title: Infliximab therapy induces increased polyclonality of CD4+CD25+ regulatory T cells in psoriasis.
authors.forename: L
authors.initials: L
authors.lastname: Diluvio
authors.forename: M L
authors.initials: ML
authors.lastname: Romiti
authors.forename: F
authors.initials: F
authors.lastname: Angelini
authors.forename: E
authors.initials: E
authors.lastname: Campione
authors.forename: P
authors.initials: P
authors.lastname: Rossi
authors.forename: J C
authors.initials: JC
authors.lastname: Prinz
authors.forename: S
authors.initials: S
authors.lastname: Chimenti
authors.forename: A
authors.initials: A
authors.lastname: Lamioni
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D015704:CD4 Antigens; D003879:Dermatologic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D000069285:Infliximab; D053645:Interleukin-2 Receptor alpha Subunit; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D050378:T-Lymphocytes, Regulatory / Q000166:cytology / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D003879:Dermatologic Agents; D053645:Interleukin-2 Receptor alpha Subunit; D000069285:Infliximab